𝔖 Bobbio Scriptorium
✦   LIBER   ✦

LONG-TERM FOLLOW-UP OF ADRENOCORTICAL CARCINOMA PATIENTS TREATED WITH ADJUVANT LOW-DOSE MITOTANE (O, P', -DDD)

✍ Scribed by M. Mullerad; G. Dickstein; C. Shechner; G. Meyer; B. Moskovitz; O. Nativ

Book ID
118647670
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
49 KB
Volume
5
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Plasma level monitoring of mitotane (o,p
Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of cushing's disease with low doses
✍ R. Benecke; E. Keller; B. Vetter; R. A. Zeeuw πŸ“‚ Article πŸ“… 1991 πŸ› Springer 🌐 English βš– 345 KB

Mitotane (o,p'-DDD) can be used for the treatment of various adrenocortical diseases such as Cushing's syndrome, but the usual doses of 6-8 g per day are often associated with severe adverse effects. This paper reports the results of much lower doses of o,p'-DDD (0.5-2 g per day) in two patients wit

Long term follow-up of women treated wit
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma
✍ Bahar Mikhak; Marianna Zahurak; Martin D. Abeloff; John H. Fetting; Nancy E. Dav πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

## Background: A phase ii study was performed evaluating the disease free and overall survival rates associated with a dose-intensive, 16-week, doxorubicin-based adjuvant chemotherapy regimen in women with breast carcinoma and > or = 10 involved axillary lymph nodes. ## Methods: Eligible patients